CARING, SERVING, SUPPORTING
Our Research Dollars
  • $150,000 grant to The University of Texas MD Anderson Cancer Center for Overcoming stromal-mediated drug resistance cells: the role of fatty acid metabolism in the Warburg effect - Ismael J. Samudio, Ph.D., Principal Investigator. This is a Young Investigator Award to Dr. Samudio.
  • $150,000 grant to UT Health Science Center at San Antonio for Aurora A: A Novel Therapeutic Target for Imatinib, Desatinib, Nilotininb and Bosutinib-Resistant Chronic Myeloid Leukemia and Ph Acute Lymphoblastic Leukemia - Jennifer Carew, Ph.D. and Frank Giles, M.D., Principal Investigators. This is a Young Investigator Award to Dr. Carew.
  • $150,000 grant to The University of Texas Southwestern Medical Center for Development of a novel targeted therapy for acute and chronic leukemias - Pier Paolo Scaglioni, Ph.D., Principal Investigator.
  • Leukemia Texas Research$191,530 grant to Baylor Research Institute for Development of a Cancer Cell Vaccine for Treatment of Multiple Myeloma and Plasma Cell Leukemia. This new study utilized translation studies to explore developing a cancer cell vaccine as a new treatment for Plasma Cell Leukemia and Multiple Myeloma.
  • $300,000 grant to The University of Texas Southwestern Medical Center for Allodepleted T-Cell Infusions in Patients Receiving Nonmyeloablative Hematopoietic Stem Cell Transplants. This new study gathered allogeneic hematopoietic cell transplantation data and utilized selective allodepletion to decrease graft vs host disease.
  • $362,861 grant to Baylor Research Institute for The Effect of HLA Mismatches on the Outcome of Unrelated Donor-Bone Marrow Transplants in the Treatment of Leukemia and Lymphoma. This study has resulted in an improved allogeneic bone marrow transplant process while reducing immunologic complications due to imperfect tissue matching.
  • $225,000 grant to The University of Texas Southwestern Medical Center for The Study of Mechanisms of Graft vs Host Disease Using Quantitative Assay of Antigen-Specific T Cells. This study applied to all types of leukemia and has produced a completely new and improved treatment methodology for allogeneic stem cell transplantations.
  • $25,000 grant to Dr. Alan Miller and his team of investigators at Baylor Scott & White Health for the study to identify a bio marker that is cost effective and minimally invasive for monitoring AML, the response to therapy, and progression to treatments in up to 100 patients across Texas to improve the survival rates. 
  • $15,000 to UT Southwestern Medical Center from proceeds from the inaugural Dance for Reagan event in honor of Reagan McDonald and her courageous battle with leukemia. 
  • $80,000 to Dr. Premal Lulla and his team of investigators at Baylor College of Medicine, Center for Cell & Gene Therapy for the study of adoptively transferred leukemia antigen-specific T-cells as treatment for Acute Myeloid Leukemia relapse after an allogenic hematopoietic stem cell transplant. 
  • $20,000 to Dr. Courtney DiNardo at The University of Texas MD Anderson Cancer Center for her study of D2HG Levels in AML Patients with IDH1/2 Mutations.
  • $20,000 to Dr. Philip Thompson at The University of Texas MD Anderson Cancer Center for his study of Identifying Immunologic Predictors of Response and Resistance to Blinotumomab Therapy in Pre-B cell ALL.
  • $20,000 to Dr. Paul Trippier at Texas Tech University Health Sciences Center for his study of Development of AKR1C# Inhibitors for the Treatment of Leukemia.